Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calcium-channel blocking agents.

R G Leonard, R L Talbert

    Clinical Pharmacy
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Calcium-channel blockers like verapamil, nifedipine, and diltiazem impact cardiovascular function by altering calcium flow. These agents offer therapeutic options for various heart conditions, expanding treatment possibilities.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Antiplatelet therapy in secondary stroke prevention.

    Expert opinion on pharmacotherapy·2002
    Same author

    A call for pharmacists to improve the care of patients with myocardial infarction.

    Pharmacotherapy·2001
    Same author

    Lipid management by pharmacists: evidence of benefits.

    Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2000
    Same author

    Thrombolytic therapy for acute myocardial infarction.

    Pharmacotherapy·1998
    Same author

    Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group.

    Stroke·1998
    Same author

    The pharmacist's perspective on newer thrombolytic therapies for acute myocardial infarction.Introduction.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1997
    Same journal

    Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

    Clinical pharmacy·1993
    Same journal

    Accuracy of unbound-quinidine concentration determination after ultrafiltration.

    Clinical pharmacy·1993
    Same journal

    Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

    Clinical pharmacy·1993
    Same journal

    Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

    Clinical pharmacy·1993
    Same journal

    Efficacy of nutritional supplements used by athletes.

    Clinical pharmacy·1993
    Same journal

    Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

    Clinical pharmacy·1993
    See all related articles

    Area of Science:

    • Cardiovascular Pharmacology
    • Clinical Therapeutics

    Background:

    • Calcium ions are critical for cardiovascular function, influencing cardiac action potentials, myocardial contractility, and vascular smooth muscle tone.
    • Calcium-channel blocking agents modulate calcium ion influx into cardiac and smooth muscle cells, affecting cardiovascular dynamics.

    Purpose of the Study:

    • To review the pharmacology, pharmacokinetics, and clinical applications of three calcium-channel blockers: verapamil hydrochloride, nifedipine, and diltiazem hydrochloride.
    • To elucidate the role of these agents in managing cardiovascular diseases.

    Main Methods:

    • Review of existing literature on verapamil hydrochloride, nifedipine, and diltiazem hydrochloride.
    • Analysis of pharmacological properties, pharmacokinetic profiles, and clinical study data for each agent.

    Related Experiment Videos

    Main Results:

    • Verapamil is effective for supraventricular rhythm disturbances; nifedipine is useful for hypertension and angina; diltiazem shows promise for coronary spasm and angina.
    • Each agent exhibits distinct effects on calcium channels, with varying pharmacokinetic profiles and side effect incidences.
    • Verapamil has contraindications including sinus-node disease and AV block; nifedipine's side effects relate to vasodilation; diltiazem shows bioavailability variability.

    Conclusions:

    • Calcium-channel blockers represent a significant addition to the therapeutic options for cardiovascular diseases.
    • Further research is needed to fully define the clinical role and optimal use of these agents.